Background: The electronic health record (EHR) contains a wealth of clinical data that may be used to streamline the identification of potential clinical trial participants. However, there is little empirical information on site-level facilitators of and barriers to optimal use of EHR systems with respect to trial recruitment.
Methods: We conducted qualitative focus groups and quantitative surveys as part of the EHR Ancillary Study, which is being conducted alongside the multicenter, global, Harmony Outcomes Trial comparing albiglutide to standard care for the prevention of cardiovascular events in type 2 diabetes. Subject matter experts used findings from focus groups to draft a 20-question survey examining the use of the EHR for participant identification, common site recruitment strategies, and variation in perceived barriers to optimal use of the EHR. The final survey was fielded with 446 site investigators actively enrolling participants in the main trial.
Results: Nearly two-thirds of respondents were study coordinators (63.2%), 23.1% were principal investigators, and 13.7% held other research roles. Approximately half of the respondents reported using the EHR to find potential trial participants. Of these, 79.4% reported using EHR searches in conjunction with other recruitment methods, including reviewing of upcoming clinic schedules (75.3%) and contacting past trial participants (71.2%). Important barriers to optimal use of the EHR included the lack of availability of certain research-focused EHR modules and limitations on the ability to contact patients cared for by other providers. Of survey respondents who did not use the EHR to find potential participants, one-quarter reported that the EHR was not accessible in their country; this finding varied from 2.6% of respondents in North America to 50% of respondents in the Asia Pacific.
Conclusions: While EHR screening was commonly used for recruitment in a cardiovascular outcomes trial, important technical, governance, and regulatory barriers persist. Multifaceted, scalable, and customizable strategies are needed to support the optimal use of the EHR for trial participant identification.
Trial Registration: ClinicalTrials.gov NCT02465515. Registered on 8 June 2015.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287813 | PMC |
| http://dx.doi.org/10.1186/s13063-021-05397-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Derivation and Validation of D-RISK: An Electronic Health Record-Driven Risk Score to Detect Undiagnosed Dysglycemia in Clinical Practice.
Diabetes Care
January 2025
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Objective: We derive and validate D-RISK, an electronic health record (EHR)-driven risk score to optimize and facilitate screening for undiagnosed dysglycemia (prediabetes + diabetes) in clinical practice.
Research Design And Methods: We used retrospective EHR data (derivation sample) and a prospective diabetes screening study (validation sample) to develop D-RISK. Logistic regression with backward selection was used to predict dysglycemia (HbA1c ≥5.
Toward a Computable Phenotype for Determining Eligibility of Lung Cancer Screening Using Electronic Health Records.
JCO Clin Cancer Inform
January 2025
Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL.
Purpose: Lung cancer screening (LCS) has the potential to reduce mortality and detect lung cancer at its early stages, but the high false-positive rate associated with low-dose computed tomography (LDCT) for LCS acts as a barrier to its widespread adoption. This study aims to develop computable phenotype (CP) algorithms on the basis of electronic health records (EHRs) to identify individual's eligibility for LCS, thereby enhancing LCS utilization in real-world settings.
Materials And Methods: The study cohort included 5,778 individuals who underwent LDCT for LCS from 2012 to 2022, as recorded in the University of Florida Health Integrated Data Repository.
Type 2 Diabetes Disease and Management Patterns Across a Large, Diverse Healthcare System: Issues and Opportunities for Guideline-Directed Therapies.
Am Heart J
January 2025
Accelerator for Clinical Transformation, Brigham and Women's Hospital, Boston, MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:
Background: The prevalence, chronicity and clinical impact of type 2 diabetes (T2D) defines this disease state as a critical determinant in morbidity and mortality, as encountered by individuals, health care systems, and public health in general. The need to understand and optimize T2D identification and management is now further heightened by the advent of medications with established cardiovascular (CV) and kidney benefits in such patients, namely sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA). Prescription rates for these agents have remained low despite guidelines incorporating and emphasizing their use.
View Article and Find Full Text PDFReal-Time Analytics and AI for Managing No-Show Appointments in Primary Health Care in the United Arab Emirates: Before-and-After Study.
JMIR Form Res
January 2025
Oracle, The Edge Building, Al Falak Street, Dubai Internet City, Dubai, United Arab Emirates, 971 558620820.
Background: Primary health care (PHC) services face operational challenges due to high patient volumes, leading to complex management needs. Patients access services through booked appointments and walk-in visits, with walk-in visits often facing longer waiting times. No-show appointments are significant contributors to inefficiency in PHC operations, which can lead to an estimated 3%-14% revenue loss, disrupt resource allocation, and negatively impact health care quality.
View Article and Find Full Text PDFAssessing the Landscape of AI-Powered Patient Documentation in Dermatology.
J Drugs Dermatol
January 2025
Background: The prevalence of burnout among United States (US) dermatologists has surged, reaching 49% in 2023, with a growing volume of bureaucratic tasks (eg, charting, paperwork) the leading factor behind professional fatigue. We seek to explore the competitive landscape and efficacy of AI-powered patient documentation to alleviate burnout among dermatologists by optimizing documentation practices while maintaining accuracy.
Methods: We conducted a review of eighteen AI-powered automated documentation products available in the current healthcare landscape, focusing on their integration with electronic health record (EHR) systems, HIPAA compliance, language support, mobile accessibility, and consumer type.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!